FDA approval is a scientific and regulatory achievement. It does not guarantee that a medicine will recover its development costs, sustain commercialization, or fund its next indication. BioXcel’s experience raises a practical question for emerging biopharma companies: how do you turn an approved medicine into a sustainable business?
In April 2022, the FDA approved Igalmi, a dexmedetomidine film for acute agitation associated with schizophrenia or bipolar I or II disorder in adults. In 2025, BioXcel reported $642,000 in net product revenue against $57.6 million in company-wide operating cash outflow.[1,2]
BioXcel filed for Chapter 11 in August 2026, approximately eleven weeks before the November 14 FDA target decision date for an at-home indication. That expansion could broaden the commercial opportunity, but the company’s financing needs could not wait.[3,4] Its experience offers four lessons about bringing a new medicine to market.
1. Clinical fit determines the reachable market
Igalmi is administered under the tongue or behind the lower lip under healthcare-provider supervision, with monitoring of vital signs and alertness. Its use requires suitable patients and a workable monitoring process.[5]
Hospitals already had established approaches to agitation, including antipsychotics and benzodiazepines, with oral administration preferred when patients could cooperate. BioXcel needed to establish where Igalmi fit within those pathways and when clinicians should choose it over familiar alternatives.[6]
Price sharpened that question. A 2022 San Mateo County formulary review listed wholesale acquisition costs of $105 per dose for Igalmi, $23 for generic intramuscular olanzapine, and $47 for generic intramuscular ziprasidone.[7] List prices, however, do not fully reflect manufacturer revenue: Bondoro’s summary of court filings describes an illustrative Igalmi transaction yielding approximately 42% of list price after discounts and fees.[8] That figure represents manufacturer net revenue, not the hospital’s acquisition cost, and does not establish value relative to competing treatments. At the time, the county review noted the absence of published comparisons with those injectables and recommended prior authorization requiring failure of, intolerance to, or a contraindication to olanzapine. These were local recommendations, not nationwide requirements.[7]
· Market access and HEOR implication: Comparative studies could assess time to adequate calming, rescue medication, restraint use, staff time, and adverse events. A hospital-specific budget-impact analysis could incorporate the actual treatment mix, purchasing terms, and monitoring costs. Together, these approaches could help buyers determine whether clinical or operational benefits justify the additional cost. These are proposed evidence priorities, not demonstrated benefits of Igalmi.
2. Formulary access must translate into sustained use and revenue
BioXcel reported more than 130 hospital formulary wins by May 2023, with over half of ordering hospitals having reordered. By August, approvals exceeded 185. That month, however, the company announced a commercial restructuring intended to reduce related expenses by 80%.[9,10]
Those wins demonstrated access and some repeat purchasing, but revenue remained insufficient to sustain the business. BioXcel initially estimated Q2 2024 net revenue at approximately $1.1 million; reported Q3 revenue was $214,000. Full-year revenue declined from $2.266 million in 2024 to $642,000 in 2025.[2,11,12]
BioXcel attributed the annual decline to lower bulk purchases, larger group purchasing organization discounts, and reduced commercial activity. These factors make revenue an imperfect measure of patient use and mean that 2025 sales cannot establish the product’s market potential under sustained commercial support.[13]
3. A partner can provide capital and capabilities, but cannot guarantee adoption
Adasuve, an inhaled treatment for agitation, offers a relevant precedent. Following its 2012 approval, Alexza licensed U.S. rights to Teva for $40 million upfront and up to $195 million in milestones. The agreement also included royalties and access to additional financing.[14]
Teva launched Adasuve in March 2014. Alexza subsequently reported lower sales projections and reacquired U.S. commercial rights in February 2016. Adasuve’s bronchospasm risk and restricted distribution requirements limit direct comparison with Igalmi. Nevertheless, its experience illustrates that an established commercial partner does not ensure a successful launch.[15]
For BioXcel, an earlier partnership might have provided capital, hospital relationships, evidence-generation support, and implementation expertise. Upfront payments and committed development funding could also have reduced reliance on debt while supporting the at-home program. Whether such an agreement was available—or would have prevented bankruptcy—is unknown.
The lesson is to evaluate a partner’s funding commitments and ability to address adoption barriers alongside its sales reach.
4. Financing must withstand slow adoption and regulatory delays
BioXcel drew $100 million across its 2022 loan and revenue-interest arrangements.[13] Bondoro reports that approximately $112 million in secured debt remained outstanding at bankruptcy.[8] The 2025 annual report documents a fixed annual interest rate of 13% and quarterly principal repayments scheduled to begin in March 2026.[13]
Low sales were part of a broader financing problem. According to Bondoro’s account, trial-related setbacks impaired fundraising, and BioXcel approached more than 40 potential acquirers and more than 40 financing partners before bankruptcy.[8] Those efforts did not secure a workable solution outside bankruptcy.
Teva’s proposed opening bid offers $57.5 million upfront and up to $67.5 million in contingent payments, subject to the bankruptcy sale process and closing conditions.[4] The contingent payments focus on at-home approval and commercialization. This structure highlights the importance of future expansion, but does not disclose a separate valuation for the existing supervised-use business.[8]
What to ask before the next launch
Commercial sustainability depends on adoption, net price, operating costs, and financing that can withstand delays. Before launch, ask:
· Which patients and episodes are realistically treatable?
· What evidence will justify the product’s price and place in care?
· How will formulary approval translate into stocking, repeat orders, and routine use?
· What revenue remains after discounts, fees, rebates, and returns?
· Can financing withstand slower adoption or a delayed indication expansion?
· When could a partner add the capital and capabilities the company needs?
Retaining commercial rights creates value only when a company can finance and execute the work those rights require. Commercial planning must begin well before approval and continue through adoption.
Background: BioXcel Therapeutics and Igalmi
Company origins. BioXcel Therapeutics was a subsidiary of BioXcel Corporation, later BioXcel LLC. It used the EvolverAI platform to identify new uses for existing or previously tested drugs. They identified four candidates, including BXCL501, which became Igalmi, and the oncology candidate BXCL701. BioXcel Therapeutics went public in 2018, raising approximately $54.2 million in net proceeds, according to Bondoro’s company history.[8]
Commercial operations. Igalmi launched in July 2022, three months after approval. BioXcel relies on contract manufacturer ARx to produce the film.[13] Bondoro reports that Cardinal Health supports storage and distribution through wholesalers serving healthcare facilities.[8]
Original financing. The 2022 funding package came from funds affiliated with Oaktree Capital Management and the Qatar Investment Authority. It offered a secured loan facility of up to $135 million and a revenue-interest facility of up to $120 million. BioXcel drew $70 million under the loan facility in April 2022 and $30 million under the revenue-interest arrangement in July 2022. The remaining funding was conditional rather than immediately available.[13]
Planning an evidence strategy for launch or indication expansion? Talk with Polygon Health Analytics about the data needed to assess treatment patterns, outcomes, and economic value.
References
1. U.S. Food and Drug Administration. Igalmi NDA 215390 approval letter. April 5, 2022.
2. BioXcel Therapeutics. Fourth quarter and full-year 2025 financial results. March 27, 2026.
3. BioXcel Therapeutics. Form 8-K: Chapter 11 filing. U.S. Securities and Exchange Commission. August 28, 2026.
4. Teva Pharmaceutical Industries. Proposed acquisition of a novel neuroscience product. August 28, 2026.
5. BioXcel Therapeutics. IGALMI (dexmedetomidine) sublingual film prescribing information. Revised July 2022.
6. Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project BETA Psychopharmacology Workgroup. West J Emerg Med. 2012;13(1):26–34. doi:10.5811/westjem.2011.9.6866.
7. San Mateo County Health. IGALMI (dexmedetomidine) formulary review. 2022. Pages 4–5; pricing as of June 1, 2022.
8. Bondoro. Case summary: BioXcel Therapeutics Chapter 11. September 3, 2026.
9. BioXcel Therapeutics. First quarter 2023 financial results and recent operational highlights. May 8, 2023.
10. BioXcel Therapeutics. Second quarter 2023 financial results and strategic reprioritization. August 14, 2023.
11. BioXcel Therapeutics. Preliminary estimated unaudited second quarter net revenues from sales of IGALMI. July 16, 2024.
12. BioXcel Therapeutics. Third quarter 2024 financial results. November 14, 2024. Press release reproduced by BioSpace.
13. BioXcel Therapeutics. Annual report on Form 10-K for the year ended December 31, 2025. Filed March 27, 2026. Printed pages: manufacturing, p. 23; revenue, p. 122; financing, pp. 126–129.
14. Teva Pharmaceuticals USA and Alexza Pharmaceuticals. Teva and Alexza announce Teva’s license to market ADASUVE in the U.S.. May 8, 2013.
15. Alexza Pharmaceuticals. Form 10-Q for the quarter ended March 31, 2016. Filed May 13, 2016.
All online sources accessed September 15, 2026.
Other Posts You Might Like
